NexTGen: Next-Generation T cell therapy for childhood cancers
Official title: NexTGen - DFCI
Funded at Dana-Farber Cancer Inst · NIH-11539615 · Data updated 2026-11-12
A charity-friendly overview: researchers at Dana-Farber are developing advanced engineered T-cell therapies to treat pediatric solid cancers like brain tumors and sarcomas.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 26, 2023 |
| Project end | May 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $581,692 |
| NIH project number | 3OT2CA291436-01S3 |
| Project ID | NIH-11539615 on NIH RePORTER |
Who could benefit from this research
✓Could help
Children and young adults with solid tumors (e.g., pediatric sarcomas and brain tumors) who may be eligible for engineered T-cell therapies.
✕Less likely to help
Not all patients will respond to engineered T-cell therapies, and some may experience treatment-related risks.
What this research studies
This project aims to create safer, more effective T-cell therapies for children with solid tumors. By studying primary pediatric tumors and the tumor microenvironment, the team plans to identify new targets and refine T-cell engineering. A closely linked clinical development plan will help translate lab discoveries into progressively tested treatments for kids in need.
Why it matters
Potential benefit: If successful, this program could lead to new, durable treatments that improve survival and quality of life for children with hard-to-treat solid cancers.
How similar studies have gone: Engineered T-cell therapies have shown promise in hematologic cancers, guiding this pediatric-focused effort to address solid tumors.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Majzner, Robbie G. — Dana-Farber Cancer Inst
- Study coordinator: Majzner, Robbie G.
Related research
Other NIH-funded projects on the same topics.
-
Helping young people with cancer understand their genetic risks
This study is creating a special program to help teenagers and young adults with hereditary cancer risks learn about their health and make smart choices, while also supporting their families along the way.
-
Core administrative hub for a multifaceted cancer center program
A large, international cancer research program at Dana-Farber aims to advance a curative strategy for multiple myeloma by coordinating translational research, clinical trials, and data analysis.
-
Automated, interactive lab tool to define radiation targets in cancer care
Aims to make it easier and safer to outline the area to treat in radiation therapy for cancers by using smart software and a patient-friendly interface.
-
Cancer Atlas Network data hub to share big cancer data
A national project helps researchers store, harmonize, and share large cancer data collections so doctors and scientists can learn from many patients.
-
Bridge-building cancer research partnership for education, outreach, and science
A joint effort between UMass Boston and Harvard Cancer Consortium to accelerate cancer research and education by connecting lower-resourced institutions with a leading cancer center.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.